• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Vanderbilt researchers find novel mechanism of resistance to anti-cancer drugs

Bioengineer by Bioengineer
October 16, 2017
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment. Researchers seeking to understand mechanisms of intrinsic and acquired resistance have focused on gene mutations, such as activating mutations in the oncogene KRAS.

Now, Vanderbilt investigators have discovered a novel non-genetic cause of resistance to cetuximab. Their findings, reported Oct. 16 in Nature Medicine, suggest a strategy for overcoming this resistance.

"It's sort of like we've all been looking under the light post – we look at genes, and we find mutations," said Robert Coffey Jr., M.D., Ingram Professor of Cancer Research and senior author of the current study. "What we found is that there is another form of resistance. It's not due to mutations in genes; it's an epigenetic mode of drug resistance."

Coffey and his colleagues used a 3-D cell culture system they developed to grow colon cancer cells, which were initially sensitive to cetuximab. After four months of cetuximab exposure, colonies of resistant cells grew in the culture system.

The researchers evaluated the cells for gene mutations linked to cetuximab resistance, but they didn't find any.

"Once we had excluded all known genetic causes of resistance, we figured something interesting was happening, and that led us to dig deeper," said Coffey, who is also professor of Medicine and Cell and Developmental Biology and director of the Epithelial Biology Center.

The investigators found increased expression of a long non-coding RNA called MIR100HG, which houses two microRNAs, miR-100 and miR-125b, that also had increased expression. Long non-coding RNAs and microRNAs are transcribed from the genome just like genes, but they do not encode proteins. Instead, these pieces of RNA coordinate complex epigenetic processes to regulate gene expression.

Coffey and his colleagues discovered that miR-100 and miR-125b collectively suppressed the expression of five different genes that are negative regulators of the Wnt signaling pathway. Removing these "brakes" resulted in increased Wnt signaling, which is known to promote cell proliferation.

When the investigators blocked Wnt signaling using both genetic and pharmacologic inhibitors, they were able to restore responsiveness to cetuximab in cultured colon cancer cells and in colorectal tumors in mice.

The researchers also examined tumor samples from patients with colorectal cancer who received cetuximab therapy and developed resistance to it. They found increased MIR100HG, miR-100 and miR-125b in six out of 10 patients. Tumors from two of the six patients also had genetic mutations. "We found that genetic and epigenetic resistance mechanisms can co-occur," Coffey said.

In addition, the same epigenetic mechanisms were present in other colon cancer cell lines and in head and neck cancer cell lines with both intrinsic and acquired resistance.

The findings suggest that epigenetic regulation to increase Wnt signaling may be a general mechanism cancer cells use to overcome therapeutic blockade of EGFR signaling.

For patients who are eligible for cetuximab (they're not already resistant because of known genetic mutations), it could be worthwhile to evaluate expression of MIR100HG and if it's elevated, to block Wnt signaling, Coffey said.

"Right now there aren't great drugs available to block Wnt signaling, but there are trials underway with a slew of different Wnt inhibitors," he said. "Ultimately, we could imagine giving cetuximab with a drug that would block Wnt – to enhance the activity of cetuximab or to prevent the emergence of resistance."

Coffey and his colleagues are using the 3-D culture system to explore mechanisms of drug resistance in other colon cancer cell lines. They are also developing ways to introduce selective blockers of microRNAs ("antagomiRs"), and their preliminary data suggest this strategy may confer cetuximab sensitivity to colon cancer cell lines with KRAS mutations.

###

Coffey noted the key contributions of his team members and collaborators, particularly two former postdoctoral fellows, Yuanyuan Lu, Ph.D., and Xiaodi Zhao, Ph.D., senior research specialist Ramona Graves-Deal, and Vanderbilt faculty members Qi Liu, Ph.D., James G. Patton, Ph.D., and Ethan Lee, M.D., Ph.D.

This research was supported by the National Institutes of Health (grants CA046413, CA197570, CA095103), the Natural Science Foundation of China, the National Key R&D Program and the Emmy Noether-Programme of the German Research Foundation. Coffey recently received a prestigious Outstanding Investigator Award from the National Cancer Institute.

Media Contact

Leigh MacMillan
[email protected]
615-322-4747

http://www.mc.vanderbilt.edu/npa

http://dx.doi.org/10.1038/nm.4424

Share13Tweet7Share2ShareShareShare1

Related Posts

blank

Revolutionary Classifier Uncovers Prokaryotic Efflux Proteins

October 6, 2025
N6-methyladenosine Enhances Pork Muscle Quality via Myofiber Regulation

N6-methyladenosine Enhances Pork Muscle Quality via Myofiber Regulation

October 6, 2025

Whole Genome Analysis Uncovers Variations in Goat Pigmentation

October 5, 2025

LINC01547 Enhances Pancreatic Cancer and Chemoresistance

October 5, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    95 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    93 shares
    Share 37 Tweet 23
  • New Insights Suggest ALS May Be an Autoimmune Disease

    71 shares
    Share 28 Tweet 18
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
>

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Can Targeting Inflammation Alleviate Fatigue in Early-Stage Breast Cancer Patients?

Advancing Health Recommender Systems: A New Nursing Framework

Age, Insects Shape Cadaver Microbes, Aid PMI

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.